Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:22:53 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:RPRX - ROYALTY PHARMA PLC - http://www.reprosrx.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RPRX - Q0.239.00·45.001.044.65+0.551.23,535.2155,80528,33944.31  44.925  43.9544.35  29.6616:34:33Jan 2015 min RT 2¢

Recent Trades - Last 10 of 28339
Time ETExPriceChangeVolume
16:34:33Q44.57250.472525
16:31:55Q44.640.5450
16:26:26Q44.640.5415
16:25:33Q44.640.5427
16:14:15Q44.16430.06431
16:10:04Q44.650.551
16:10:04Q44.650.551
16:10:04Q44.650.551
16:10:04Q44.650.551
16:08:13Q44.650.55580

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-20 16:15U:RPRXNews ReleaseRoyalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
2026-01-12 07:15U:RPRXNews ReleaseRoyalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
2026-01-11 17:15U:RPRXNews ReleaseRoyalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
2026-01-11 17:00U:RPRXNews ReleaseTeva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
2026-01-09 08:30U:RPRXNews ReleaseRoyalty Pharma Announces Dividend Increase
2025-12-29 16:40U:RPRXNews ReleaseRoyalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
2025-12-16 07:15U:RPRXNews ReleaseRoyalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
2025-12-12 10:47U:RPRXNews ReleasePancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
2025-12-04 07:10U:RPRXNews ReleaseRoyalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
2025-12-04 07:00U:RPRXNews ReleaseDenali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
2025-11-26 08:15U:RPRXNews ReleaseRoyalty Pharma to Present at Upcoming Investor Conferences
2025-11-05 07:00U:RPRXNews ReleaseRoyalty Pharma Reports Third Quarter 2025 Results
2025-11-04 07:15U:RPRXNews ReleaseRoyalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
2025-10-17 08:15U:RPRXNews ReleaseRoyalty Pharma Declares Fourth Quarter 2025 Dividend
2025-10-09 16:15U:RPRXNews ReleaseRoyalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
2025-09-29 08:15U:RPRXNews ReleaseRoyalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
2025-09-19 16:25U:RPRXNews ReleaseRoyalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum
2025-09-11 07:00U:RPRXNews ReleaseRoyalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
2025-09-10 07:30U:RPRXNews ReleaseRoyalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market